A Randomized, Double-Blind, Positive-Controlled, Placebo-Controlled, 4-Period Crossover Study to Investigate the Electrocardiographic Effects of BMS-986165 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2018
Price : $35 *
At a glance
- Drugs BMS 986165 (Primary) ; Moxifloxacin
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 27 Sep 2018 Status changed from recruiting to completed.
- 17 Jul 2018 Status changed from not yet recruiting to recruiting.
- 01 Jun 2018 New trial record